Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present). (Q38131552)

29 August 2017

title

Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present). (English)

1 reference

29 August 2017

Cheng Jiang

1

1 reference

29 August 2017

Qidong You

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

26 August 2013

1 reference

Expert Opinion on Therapeutic Patents

29 August 2017

published in

1 reference

29 August 2017

volume

23

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

1547-1560

1 reference

Past and future of the mitotic spindle as an oncology target

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Motor function in the mitotic spindle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Inhibitors of mitotic kinesins: next-generation antimitotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Progress on kinesin spindle protein inhibitors as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Structure-activity relationships and molecular docking of novel dihydropyrimidine-based mitotic Eg5 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Cloning, enzyme characterization of recombinant human Eg5 and the development of a new inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

New chemical tools for investigating human mitotic kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Monastrol analogs: a synthesis of pyrazolopyridine, benzopyranopyrazolopyridine, and oxygen-bridged azolopyrimidine derivatives and their biological screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

HR22C16: a potent small-molecule probe for the dynamics of cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Synthesis and biological evaluation of new tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Biochemical analysis of cellular target of S-trityl-L-cysteine derivatives using affinity matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Pharmacophore identification of KSP inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Design, synthesis and evaluation of tetrahydroisoquinolines as new kinesin spindle protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Novel ATP-competitive kinesin spindle protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Structure-activity relationships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

Synthesis and biological evaluation of l-cysteine derivatives as mitotic kinesin Eg5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.833606

10.1517/13543776.2013.833606

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference